BRPI0509420A - método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico - Google Patents

método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico

Info

Publication number
BRPI0509420A
BRPI0509420A BRPI0509420-8A BRPI0509420A BRPI0509420A BR PI0509420 A BRPI0509420 A BR PI0509420A BR PI0509420 A BRPI0509420 A BR PI0509420A BR PI0509420 A BRPI0509420 A BR PI0509420A
Authority
BR
Brazil
Prior art keywords
agent treatment
reducing
inhibiting angiogenesis
antiangiogenic agent
increasing efficacy
Prior art date
Application number
BRPI0509420-8A
Other languages
English (en)
Inventor
Ellen Filvaroff
Jo-Anne S Hongo
Leon H Parker Iv
Maike Schmidt
Weilan Ye
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0509420A publication Critical patent/BRPI0509420A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"MéTODO DE REDUçãO OU INIBIçãO DA ANGIOGêNESE E MéTODO DE AUMENTO DA EFICáCIA DE TRATAMENTO COM AGENTE ANTIANGIOGêNICO". A presente invenção fornece métodos de uso de antagonista de EGFL7 para modular o desenvolvimento vascular. Também são fornecidos no presente métodos de seleção de moduladores da atividade de EGFL7. Além disso, são fornecidos métodos de tratamento utilizando antagonistas de EGFL7.
BRPI0509420-8A 2004-04-14 2005-04-14 método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico BRPI0509420A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56205404P 2004-04-14 2004-04-14
PCT/US2005/013658 WO2005117968A2 (en) 2004-04-14 2005-04-14 Compositions and methods comprising an egfl7 antagonist for modulating vascular development

Publications (1)

Publication Number Publication Date
BRPI0509420A true BRPI0509420A (pt) 2007-09-04

Family

ID=35355481

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509420-8A BRPI0509420A (pt) 2004-04-14 2005-04-14 método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico

Country Status (14)

Country Link
US (3) US20070031437A1 (pt)
EP (1) EP1734998A2 (pt)
JP (3) JP5599136B2 (pt)
KR (1) KR101227817B1 (pt)
CN (2) CN1997394B (pt)
AU (1) AU2005249377A1 (pt)
BR (1) BRPI0509420A (pt)
CA (1) CA2563445C (pt)
IL (2) IL178329A0 (pt)
MX (1) MXPA06011851A (pt)
NZ (1) NZ550110A (pt)
RU (3) RU2365382C2 (pt)
WO (1) WO2005117968A2 (pt)
ZA (1) ZA200608615B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06011851A (es) * 2004-04-14 2006-12-14 Genentech Inc Composiciones y metodos para moduilar el desarrollo vascular.
AR059851A1 (es) * 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
US8541559B2 (en) 2006-06-12 2013-09-24 Cytos Biotechnology Ag Process for producing aggregated oligonucleotides
WO2008010986A2 (en) * 2006-07-17 2008-01-24 The Board Of Trustees Of The Leland Stanford Junior University Methods of modulating angiogenesis
WO2008130719A1 (en) * 2007-04-24 2008-10-30 University Of Louisville Therapeutic beta-glucan combinations
JP2009005584A (ja) * 2007-06-26 2009-01-15 Miyazaki Prefecture ゲル化剤、凍結保存剤、細胞保存用容器、細胞の凍結保存方法、細胞の融解方法、哺乳動物の細胞
EP2235189A1 (en) * 2008-01-14 2010-10-06 Genentech, Inc. Methods for inhibiting angiogenesis using egfl8 antagonists
WO2010034155A1 (zh) * 2008-09-25 2010-04-01 中南大学湘雅医院 一种通过检测样品中eglf7来诊断肝细胞癌的试剂盒
PE20120902A1 (es) * 2009-05-08 2012-08-08 Genentech Inc Anticuerpos anti-egfl7 humanizados
RU2412251C1 (ru) * 2009-06-15 2011-02-20 Юрий Леонидович Дорохов Антитело против фактора роста эндотелия сосудов и способ продукции антитела в растении
AU2010273585B2 (en) * 2009-07-13 2015-04-23 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
BR112012013093A2 (pt) * 2009-12-21 2017-12-12 Genentech Inc ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
WO2013061112A1 (en) 2011-10-24 2013-05-02 Centre National De La Recherche Scientifique Use of egfl7 modulators for promoting or inhibiting migration of immune cells across vascular endothelium
EP2831093A4 (en) * 2012-03-27 2015-11-04 London Health Sci Ct Res Inc EGFL7-targeting or binding polypeptides and methods for inhibiting angiogenesis
US20170007495A1 (en) * 2013-11-21 2017-01-12 Mfr Products, Inc. Therapeutic device to assist in myofascial release, and method of use
RU2729161C2 (ru) * 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
CN105543183B (zh) * 2016-01-08 2019-04-12 吴帆 人肝癌细胞Egfl8基因过表达慢病毒在制备治疗肝癌药物中的应用
US11702469B2 (en) 2017-04-24 2023-07-18 Ohio State Innovation Foundation Recombinant EGFL7, EGFL7 antibodies, and uses thereof
RU2678200C1 (ru) * 2018-07-27 2019-01-24 Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии" Лекарственная пленка пролонгированного действия и способ её получения
DE212020000830U1 (de) 2020-07-28 2023-10-30 Limited Liability Company "Angiolife" Verwendung einer Kombination von Genen angiogener und neurotropher Faktoren
CN114410642B (zh) * 2021-12-31 2023-01-17 苏州大学 一种急性t淋巴细胞白血病药物靶点及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0248088A4 (en) * 1985-11-22 1988-05-03 Teijin Ltd VASCULARIZATION FACTOR AND MANUFACTURING.
EP0318488A4 (en) 1986-08-18 1990-02-26 Biota Scient Management STIMULATION OF ANGIOGENESIS AND PROMOTION OF ENDOTHELIALIZATION.
SK163598A3 (en) * 1996-05-31 1999-06-11 Scripps Research Inst Methods and compositions useful for inhibition of angiogenesis
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000053752A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
AU737132B2 (en) * 1997-06-18 2001-08-09 Zymogenetics Inc. Mammalian neuro-growth factor like protein
US20030166907A1 (en) * 1997-06-18 2003-09-04 Zymogenetics, Inc. Mammalian neuro-growth factor like protein
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US20030022293A1 (en) 1997-09-18 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6974696B2 (en) 1997-10-17 2005-12-13 Genentech, Inc. PRO853 nucleic acids
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US20030069178A1 (en) 1997-10-17 2003-04-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7105640B2 (en) 1997-10-17 2006-09-12 Genentech, Inc. Anti-pro792 antibodies
US7196165B2 (en) 1997-10-17 2007-03-27 Genentech, Inc. PRO363 polypeptides
US20030039648A1 (en) 1998-09-16 2003-02-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
US7371836B2 (en) 1998-03-27 2008-05-13 Genentech, Inc. PRO526 nucleic acids
US7202338B2 (en) 1998-03-31 2007-04-10 Genentech, Inc. PRO731 polypeptides
US7166700B2 (en) 1998-04-01 2007-01-23 Genentech, Inc. PRO703 Polypeptides
US6962797B2 (en) 1998-04-15 2005-11-08 Genentech, Inc. Nucleic acids encoding PRO615
DE19817946A1 (de) 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Uterus-Normalgewebe
AU3965799A (en) 1998-04-23 1999-11-08 Millennium Pharmaceuticals, Inc. Novel molecules of the t125-related protein family and uses thereof
US7067636B2 (en) 1998-05-06 2006-06-27 Genentech, Inc. Anti-pro 1017 antibodies
US7279553B2 (en) 1998-05-13 2007-10-09 Genentech, Inc. PRO1083 polypeptides
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7019115B2 (en) 1998-05-22 2006-03-28 Genentech, Inc. Pro1017 polypeptides
US7220835B2 (en) 1998-07-30 2007-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001054477A2 (en) 2000-01-25 2001-08-02 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2353797A1 (en) 1998-12-11 2000-06-15 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
US20030009013A1 (en) 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000058473A2 (en) 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2000063756A1 (en) 1999-04-16 2000-10-26 Fujikin Incorporated Parallel bypass type fluid feeding device, and method and device for controlling fluid variable type pressure system flow rate used for the device
US7214656B2 (en) 1999-04-28 2007-05-08 Genentech, Inc. PRO792 polypeptides
JP2003504021A (ja) 1999-07-02 2003-02-04 財団法人相模中央化学研究所 疎水性ドメインを有するヒトプロテイン並びにそれをコードするｄｎａ
US7589172B2 (en) 1999-07-20 2009-09-15 Genentech, Inc. PRO256 polypeptides
TWI265167B (en) 1999-11-29 2006-11-01 Akzo Nobel Nv 3-methylene steroid derivatives
US7193050B2 (en) 2000-02-18 2007-03-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7442765B2 (en) 2000-08-24 2008-10-28 Genentech, Inc. Secreted transmembrane polypeptides and nucleic acids encoding the same
US7265210B2 (en) 2000-09-15 2007-09-04 Genentech, Inc. Anti-PRO9821 antibodies
WO2002076486A2 (en) * 2001-02-05 2002-10-03 Innoventus Project Ab Histidine-rich glycoprotein
US20030224984A1 (en) * 2001-06-20 2003-12-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7164007B2 (en) 2001-06-20 2007-01-16 Genentech, Inc. Anti-PR020044 antibodies
FR2851249A1 (fr) * 2003-02-17 2004-08-20 Commissariat Energie Atomique Nouveau facteur soluble secrete par les cellules endotheliales des vaisseaux sanguins, capable d'inhiber le recrutement des cellules perivasculaires du type musculaire lisse et ses applications
MXPA06011851A (es) 2004-04-14 2006-12-14 Genentech Inc Composiciones y metodos para moduilar el desarrollo vascular.

Also Published As

Publication number Publication date
AU2005249377A1 (en) 2005-12-15
US8790646B2 (en) 2014-07-29
MXPA06011851A (es) 2006-12-14
JP5599136B2 (ja) 2014-10-01
EP1734998A2 (en) 2006-12-27
US20070031437A1 (en) 2007-02-08
RU2006140081A (ru) 2008-05-20
CN1997394A (zh) 2007-07-11
JP2007532685A (ja) 2007-11-15
WO2005117968A3 (en) 2006-06-08
RU2013146239A (ru) 2015-04-27
CA2563445A1 (en) 2005-12-15
CA2563445C (en) 2016-07-19
IL178329A0 (en) 2007-02-11
IL226899A0 (en) 2013-07-31
US20090297512A1 (en) 2009-12-03
CN1997394B (zh) 2012-11-28
CN102895663A (zh) 2013-01-30
KR101227817B1 (ko) 2013-01-29
JP2011241230A (ja) 2011-12-01
RU2365382C2 (ru) 2009-08-27
KR20070029687A (ko) 2007-03-14
WO2005117968A2 (en) 2005-12-15
JP2013256535A (ja) 2013-12-26
ZA200608615B (en) 2008-05-28
US20120003208A1 (en) 2012-01-05
NZ550110A (en) 2009-09-25
RU2009114508A (ru) 2010-10-27

Similar Documents

Publication Publication Date Title
BRPI0509420A (pt) método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico
TR200102499T2 (tr) Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
ATE544866T1 (de) Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
IS6069A (is) N-cýanómetýlamíð sem próteasalatar
DK1268481T3 (da) Inaseinkibitorer som terapeutiske midler
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
ATE293691T1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
MXPA04005003A (es) Antagonistas de endotelina en un metodo y composicion para potenciar un analgesico opiaceo.
ATE256461T1 (de) Benutzung von comt-inhibitoren als analgetika
TNSN07203A1 (en) Pharmaceutical compositions for the treatment of cellulite
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
BRPI0414724A (pt) combinação, composição farmacêutica, métodos para prevenir ou tratar aterosclerose em um animal de sangue quente e para prevenir eventos cardiovasculares em um animal de sangue quente, e, kit
DE60130659D1 (de) Therapeutische verbindungen und verfahren
BR0108980A (pt) Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
BR0111785A (pt) Composições e métodos para tratamento de candidìase
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
BR0113886A (pt) Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit
WO2007029188A3 (en) Method of using fabric care compositions to achieve a synergistic odor benefit
MXPA02012209A (es) Terapia combinada contra tumores que comprende derivados de bistamicina acriloilo substituida y agentes de alquilacion.
MXPA04011018A (es) Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias.
ZA200209835B (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or anti-metabolites.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2562 DE 11/02/2020.